Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16137952 | 1.00 | HDAC1 (0.50) | HDAC1HDAC2CYP17A1NAMPTNPC1 | |
| SCHEMBL13153892 | 1.00 | HDAC1 (0.50) | HDAC1HDAC2CYP17A1NAMPTNPC1 | |
| SCHEMBL5394826 | 0.84 | SMN1; SMN2 (0.58) | CYP17A1NAMPTNPC1RAB9AALDH1A1 | |
| SCHEMBL14503399 | 0.83 | CYP17A1 (0.51) | CYP17A1NAMPTPRMT1MAPTPSMB8 | |
| SCHEMBL4514014 | 0.83 | HDAC3 (0.53) | HDAC1HDAC2CYP17A1NAMPTRAB9A | |
| SCHEMBL8268111 | 0.83 | HDAC3 (0.53) | HDAC1HDAC2CYP17A1NAMPTRAB9A | |
| SCHEMBL13055402 | 0.82 | CYP17A1 (0.59) | CYP17A1NAMPTALDH1A1GAAPSMB8 | |
| SCHEMBL14024178 | 0.81 | CYP17A1 (0.52) | CYP17A1NAMPTNPC1RAB9AALDH1A1 | |
| SCHEMBL5464761 | 0.81 | CYP17A1 (0.52) | CYP17A1NAMPTALDH1A1PRMT1GAA | |
| SCHEMBL12637634 | 0.80 | CYP17A1 (0.57) | CYP17A1NAMPTNPC1RAB9APRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228630-B1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-03-05 | — | — | EP | disclosed |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-2978756-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Pharma AG (DE) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | HDAC1 804/4885HDAC2 1440/4885CYP17A1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.